FDC Limited has announced the successful completion of its postal ballot process for relocating the company's registered office from Maharashtra's Waluj industrial area to Mumbai. The pharmaceutical company disclosed the voting results on January 28, 2026, following the conclusion of the remote e-voting period.

Postal Ballot Results

The special resolution for shifting the registered office received overwhelming shareholder support through the electronic voting process. The detailed voting breakdown demonstrates strong consensus among all shareholder categories.

Office Relocation Details

The approved resolution authorizes FDC Limited to shift its registered office from the current location at "B-8, M.I.D.C. Industrial Area, Waluj - 431 130, Chhatrapati Sambhaji Nagar, Maharashtra, India" to "FDC House, C-11 & 12, Dalia Industrial Estate, Oshiwara Village, Off New Link Road, Andheri - West, Mumbai – 400053 Maharashtra, India."

Voting Process and Timeline

The remote e-voting process was conducted in accordance with regulatory requirements under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Key process details include:

Scrutinizer Oversight

Mr. Sanjay Dholakia, Proprietor of M/s. Sanjay Dholakia & Associates (Membership No.: FCS 2655 & C.P No. 1798), served as the appointed scrutinizer for the postal ballot process. The Board of Directors appointed him on December 19, 2025, to oversee the e-voting scrutiny and ensure compliance with regulatory requirements.

Shareholder Participation

Out of the total 162810084 shares, 127633690 shares participated in the voting process, representing a participation rate of 78.39%. The promoter and promoter group demonstrated complete participation with 100% of their shareholding, while public institutional investors showed 92.80% participation. Public non-institutional shareholders had a participation rate of 3.17%.

Regulatory Compliance

The postal ballot process was conducted pursuant to Sections 12, 108, and 110 of the Companies Act, 2013, along with applicable rules and regulations. The voting results and scrutinizer's report have been made available on the company's website at www.fdcindia.com and on NSDL's e-voting portal at www.evoting.nsdl.com , ensuring transparency and regulatory compliance.

FDC Limited has achieved a significant regulatory milestone with the receipt of approval from the United States Food and Drug Administration (USFDA) for its Fluconazole tablets. This approval encompasses multiple dosage strengths, positioning the company to serve diverse patient needs in the American pharmaceutical market.

USFDA Approval Details

The regulatory approval covers Fluconazole tablets in four distinct dosage formulations, providing healthcare providers with comprehensive treatment options for patients requiring antifungal therapy.

Strategic Market Expansion

This USFDA approval represents a crucial step in FDC Limited's international expansion strategy. Fluconazole is a widely prescribed antifungal medication used to treat various fungal infections, making it an important therapeutic option in clinical practice. The approval across multiple dosage strengths demonstrates the company's capability to develop and manufacture pharmaceutical products that meet the stringent quality and safety standards required by US regulatory authorities.

Product Portfolio Enhancement

The addition of Fluconazole tablets to FDC's USFDA-approved product portfolio strengthens the company's position in the competitive US pharmaceutical market. The availability of four different dosage strengths allows for flexible dosing regimens, catering to various patient populations and treatment protocols as determined by healthcare professionals.

This regulatory achievement underscores FDC Limited's commitment to expanding its global presence while maintaining high standards of pharmaceutical manufacturing and quality assurance. The approval enables the company to participate in the substantial US market for antifungal medications, potentially contributing to future revenue growth and market diversification.